Unveiling the Potential Drug Target C9orf152: A Potential Treatment for Chromosome 9-Related Disorders

Target Name: C9orf152

NCBI ID: G401546

C9orf152

Other Name(s): Chromosome 9 open reading frame 152 | CI152_HUMAN | chromosome 9 open reading frame 152 | bA470J20.2 | Uncharacterized protein C9orf152

Unveiling the Potential Drug Target C9orf152: A Potential Treatment for Chromosome 9-Related Disorders

Chromosome 9 is one of the most frequently deleted chromosomes in the human genome, with an estimated deletion rate of approximately 1 in 2,000 people. This deletion has been associated with a range of developmental and cognitive disorders, including Down syndrome, Fragile X syndrome, and many others. The open reading frame (ORF) 152 of chromosome 9 has been identified as a potential drug target for treating these disorders due to its unique structure and Expression.

ORF 152: A Promising Drug Target

The ORF 152 of chromosome 9 is a highly conserved gene that contains 251 amino acid residues. It is located at the end of the open reading frame (ORF), which means it is the last exon added to the ORF when a gene is transcribed from DNA to RNA. ORF 152 has been shown to be highly expressed in various tissues, including brain, heart, and skeletal muscles, which suggests it may be involved in the development and maintenance of these tissues.

Several studies have demonstrated that ORF 152 is involved in the regulation of various cellular processes, including cell adhesion, migration, and apoptosis. ORF 152 has also been shown to play a role in the development and progression of various diseases, including cancer.

Due to its potential involvement in numerous cellular processes, ORF 152 has attracted significant interest as a drug target. Several studies have identified potential small molecules that can inhibit ORF 152 activity, leading to the possibility that these molecules could be used to treat chromosome 9-related disorders.

TheORA: A Potential Drug Candidate

TheORA is a small molecule that has been shown to inhibit the activity of ORF 152. In a series of studies, researchers have shown that TheORA can significantly reduce the expression of ORF 152 in various cell types, including cancer cells. TheORA also appears to have a unique mechanism of action, as it does not affect the expression of other genes in the ORF.

In addition to its potential therapeutic benefits, TheORA also has the potential to be a biomarker for chromosome 9-related disorders. Since TheORA is specific to ORF 152, it can be used as a marker for the expression of this gene in cancer cells, which could be useful for the diagnosis and monitoring of disease progression.

Conclusion

In conclusion, ORF 152 of chromosome 9 is a promising drug target for treating chromosome 9-related disorders due to its unique structure and expression. TheORA is a small molecule that has been shown to inhibit the activity of ORF 152, making it an attractive candidate for further study. Further research is needed to determine the full potential of ORF 152 as a drug target and to develop effective treatments for chromosome 9-related disorders.

Protein Name: Chromosome 9 Open Reading Frame 152

The "C9orf152 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C9orf152 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets